Susceptibility testing of fungi and correlation with clinical outcome

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 1, 1997, Pages 19-24

  Ghannoum, M A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Candidiasis; Clinical outcome; Fluconazole; Fungal infections; Itraconazole; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; TERBINAFINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; CANDIDIASIS; CONFERENCE PAPER; DILUTION; HUMAN; INFECTION SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCOSES; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0030737808     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989; 8:323-330.
2. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991; 91 (Suppl 3B):86-89.
3. Pfaller MA, Wenzel R. The impact of changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992; 11:287-291.
4. Richardson MD. Opportunistic and pathogenic fungi. J Antimicrob Chemother 1991; 28 (suppl A): 1-11.
5. Horsburgh CR, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 1983; 74:23-29.
6. Merz WG. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984; 20: 1194-1195.
7. Stiller RL, Bennett JE, Scholer HJ, Wall M, Polak A, Stevens DA. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982; 22: 482-487.
8. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
9. Ghannoum MA. Future of antimycotic therapy. Dermatology Therapy (in press) 1997.
10. Espinel-Ingroff A, Kerkering TM, Goldson PR, Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1991; 29: 1089-1094.
11. Espinel-Ingroff A, Kish CW, Kerkering TM, et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1992; 30: 3138-3145.
12. Fromtling RA, Galgiani JN, Pfaller MA et al. Multicenter evaluation of a macrobroth antifungal susceptibility test for yeasts. Antimicrob Agents Chemother 1993; 37: 39-45.
13. Guinet R, Nerson D, DeClosets F, et al. Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing. J Clin Microbiol 1988; 26: 2307-2512.
14. Pfaller MA, Burmeister L, Bartlett MS, Rinaldi MG. Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol 1988; 26: 1437-1441.
15. Pfaller MA, Rinaldi MG, Galgiani JN et al. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother 1990; 54: 1648-1654.
16. Polak A, Ansorg R, Bartmann K et al. Multizenter-Studie zur Standardisierung der Empfindlichkeitsbestimmung von Pilzen gegen 5-Fluorocytosin und Amphotericin B. Mykosen 1987; 30: 306-314.
17. Shawar R, Paetznick V, Witte Z, Ensign LG, Anaissie E, LaRocco M. Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans. J Clin Microbiol 1992; 30: 1976-1981.
18. Troke PF and the Fluconazole Susceptibility Testing Group. Standardized susceptibility testing of fluconazole: a nine-centre, international collaborative study. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1992: No. 1596.
19. National Committee tor Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; proposed standard. M27-P. National Committee tor Clinical Laboratory Standards, Villanova, PA, 1992.
20. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antitungal susceptibility testing of yeasts; proposed standard, M27-T. National Committee for Clinical Laboratory Standards, Villanova, PA, 1995.
21. Cihannoum MA, Ibrahim AS, Fu Y, Shatiq MC, Edwards JE, Criddle RS. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992; 50: 2881-2886.
22. Rex JH, Cooper Jr CR, Merz WC, Galgiani JN, Anaissie EJ. Detection of amphotericin B resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906-909.
23. Sanati H, Larsen R, Sheehan D, Ritchie J, Spelberg B, Cihannoum M. Pen assay medium produces broad range of MICs of amphotericin B (Amph B) against clinical isolates of C. neoformans in a microdilution broth assay. 95th General Meeting of the American Society for Microbiology, Washington DC, 1995: abstr. n. F103.
24. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-540.
25. Pfaller MA, Barry AL. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1994; 52: 1992-1996.
26. Tiballi RN, He X, Zarins LT, Revankar SG, Kauffman CA. Use of a colorimetric system for yeast susceptibility test ing. J Clin Microbiol 1995; 33: 915-917.
27. Wanger A, Mills K, Rex JH. Comparison of E test and macrobroth dilution for antifungal susceptibility testing. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994: N. D20.
28. Ghannoum MA. Is antifungal susceptibility testing useful in guiding fluconazole therapy? Clin Infect Dis 1996; 22 (5): 161-165.
29. Ghannoum MA, Rex J, Galgiani J. Susceptibility testing of tungi. Current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489-495.
30. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole resistant candidiasis in an HIV cohort. AIDS 1994; 8: 787-792.
31. Barchiesi F, Hollis RJ, McGough DA, Scalise G, Rinaldi MG, Pfaller MA. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis 1995; 20: 634-640.
32. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans gentotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993; 31: 2933-2937.
33. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993; 17: 1018-1021.
34. DuPont B, Improvisi L, Eliaszewicz M, Pialoux G and the GEMO. Resistance of Candida albicans to fluconazole in AIDS patients. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 1992: N. 1203.
35. Heinic GS, Stevens DA, Greenspan D et al. Fluconazolc resistant Candida in AIDS patients. Report of two cases. Oral Surg Oral Med Oral Pathol 1993; 76: 711-715.
36. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994; 19: 684-686.
37. Pfaller MA, Rhine-Chalberg J, Redding SW et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994; 32: 59-64.
38. Redding S, Smith J, Farinacci G et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation of invitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240-242.
39. Reynes J, Mallié M, André D, Janbon F, Bastide JM. Traitement et prophylaxie secondaire par fluconazole des candidoses oropharyngées des sujets VIH+. Analyse mycologique des échecs. Pathol Biol 1992; 40: 513-517.
40. Sandven P, Bjorneklett A, Maeland A, and the Norwegian Yeast Study Group. Susceptibility testing of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chcmother 1993; 37: 2443-2448.
41. Sangeorzan JA, Bradley SF, He X et al. Epidemiology of oral candidiasis in HIV infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-346.
42. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993; 12: 911-915.
43. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD, and the NIAID Mycoses Study Croup and the Candidemia Study Group. Antitungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole vs. amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-44.
44. Witt MD, Lewis RJ Larsen RA et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antitungal susceptibility testing. Clin Infect Dis 1996; 22: 322-328.
45. Larsen RA, Bozzette SA, Jones BL, Haghighat D, Leal MA. Fluconazole combined with flucytosine for cryptococcal meningitis in persons with AIDS. Clin Infect Dis (in press) 1997.
46. Milechike EN, Leal M, Haubrich R, See R, Bozzette S, Larsen R. High dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis. IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation. 1993, abstr.
47. Rex JG, Pfaller M, Galgiani J et al. Development of interpretive breakpoints for susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data tor fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-247.
48. Ganger G, Just-Nubling G, Eichel M, Hoika R, Stille W, Goethe J. Itraconazole solution in patients with nonresponse to fluconazole. IXth International Conference on AIDS, Berlin, 1993: abstr. PO-B09-1394.
49. Ng T, Denning DW. Fluconazole resistance in Candida in patients with AIDS - a therapeutic approach. J Infect 1993; 26: 117-125.